Introduction {#Sec1}
============

Leishmaniasis refers to a disease that is caused by various *Leishmania* species. It is a treatable and curable group of diseases that affects some of the poorest people on earth. They are associated with malnutrition, population displacement, poor housing conditions, and weak immune system. Cutaneous leishmaniasis (CL), the most common form, causes skin lesions and it annually affects 0.7--1.2 million people in the Americas, the Mediterranean basin, the Middle East and Central Asia. In 2013, 95% of the cases reported to WHO had occurred in 15 countries (Alvar et al. [@CR4]). In 2014, over 153,000 cases and 138,575 cases in 2015 (new cases and relapse cases) (World Health Organization (WHO) [@CR26]) were reported to WHO from 10 high-burden countries---Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru (World Health Organization (WHO) [@CR26], [@CR24].

The clinical management of CL has been based only on treating patients with pentavalent antimonial compounds, which are insufficient, toxic and cause resistance (Yasinzai et al. [@CR27]). The mechanisms of classical drug resistance are often related with lower drug uptake, increased efflux, faster drug metabolism, drug target modifications, and the over-expression of drug transporters. The high prevalence of CL and the appearance of resistance to classical drugs highlight a demand for developing and exploring novel, less toxic, low cost, and more promising therapeutic modalities (Yasinzai et al. [@CR27]).

The topical treatment of CL presents an attractive alternative that avoids the toxicities of parenteral therapy while being administered through a simple painless route. The treatments that have been used topically for leishmaniasis include paromomycin ointment, topical clotrimazole and miconazole, thermotherapy, cryosurgery using CO~2~ slush, cryotherapy by liquid nitrogen, CO~2~ laser, and currently liposome of amphotericin B (Singh and Sivakumar [@CR22]; Al-Qubati et al. [@CR3]; Alavi-Naini et al. [@CR1]; Mosimann et al. [@CR19]).

Benzoxonium chloride (C~23~H~42~∙ClNO~2~, Fig. [1](#Fig1){ref-type="fig"}) belongs to quaternary ammonium compounds of anti-infective agents that are used as anti-septic drugs and for disinfecting the mucus membrane, skin surface, and medical instruments. Benzoxonium chloride is also effective against bacteria, certain protozoa, yeasts and non-spore forming organisms (Kim et al. [@CR15]). However, studies have suggested that benzoxonium chloride inhibits certain bacterial enzymes (\[CSL STYLE ERROR: reference with no printed form.\]). In 2015, Thio-Ben was tested in a clinical trial and it evaluated the efficacy of the topical use of tioxolone plus benzoxonium chloride (Thio-Ben) tincture in combination with cryotherapy as compared to intralesional meglumine antimoniate (glucantime™) along with cryotherapy in treating anthroponotic CL (ACL) (Daie Parizi et al. [@CR9]). The study reported that the topical use of Thio-Ben combined with cryotherapy showed good efficacy in treating ACL along with benefits pertaining to more patient compliance and less side effects than intralesional glucantime (Daie Parizi et al. [@CR9]).Fig. 1Chemical structure of benzyl-dodecyl-bis (2-hydroxyethyl) azanium;chloride (benzoxonium chloride)

Recently, vesicular drug delivery systems such as phospholipid vesicles (liposomes) have been used in several types of leishmaniasis (Layegh et al. [@CR16]; Balasegaram et al. [@CR5]; Moosavian Kalat et al. [@CR18]). Non-ionic surfactant vesicles (niosomes) have also been tested for the treatment of leishmaniasis (Yasinzai et al. [@CR27]). These are biodegradable, biocompatible, reduce cytotoxicity for animal cells, more stable and relatively inexpensive, and they can be improved via the development of controlled and targeted drug-delivery formulations to overcome resistance (Hu and Rhodes [@CR13]). Given the above mentioned reasons, in this study, we investigated the *in vitro* effect of benzoxonium chloride and its niosomal forms on *Leishmania tropica* and also examined the cytotoxicity, apoptosis, and gene expression profiling of the selected formulation.

Materials and methods {#Sec2}
=====================

Materials {#Sec3}
---------

Benzoxonium chloride was purchased from BOC Sciences, USA. Meglumine antimoniate (MA, Glucantime^®^) 1.5 g/5 mL solution was obtained from Sanofi-Aventis, France. MTT powder (3-\[4, 5-dimethylthiazol-2-yl\]-2, 5-diphenyltetrazolium bromide; Thiazolyl blue), sorbitan esters (Span^®^), their PEGylated derivatives (Tween^®^) and cholesterol (CHOL) were provided by Sigma-Aldrich^®^ (USA). DMEM medium with sodium pyruvate, RPMI- 1640 medium with stable glutamine were purchased from Biosera (France) and fetal bovine serum (FBS) were prepared by Gibco (USA). Phycoerythrin (PE) Annexin V Apoptosis Detection Kit I (catalog number: 559763) was prepared by BD Pharmingen™. Phosphate buffered saline (PBS) was purchased from Cassion Lab (USA). Penicillin and streptomycin were obtained from Life Technology (USA) and was frozen at − 20 °C until testing.

Preparation of niosomes {#Sec4}
-----------------------

The thin film hydration method was used to prepare the niosomal forms (Pardakhty et al. [@CR20]). Briefly, the nonionic surfactants (Span 60 and 40 and Tween 60 and 40)/CHOL were dissolved in chloroform and mixed at different molar ratios (7:3, 6:4 and 8:2) in a round-bottom flask. The organic solvent was evaporated by a rotary evaporator (Buchi, Switzerland). The hydration of the lipid film was accomplished with 5 mL of deionized water containing 3 mg/mL of benzoxonium chloride in the round-bottom flask at 70 °C for 30 min. The resulting niosomal suspension was then maintained over night at 4 °C and stored in a refrigerator for maturation of the vesicles and further studies.

Characterization of niosomes {#Sec5}
----------------------------

The morphology and shape of the vesicles (round multilamellar vesicles; MLVs) and the probable niosomal constituents' crystallization/separation or aggregation were characterized by optical microscopy (Zeiss, Germany) and micrographs were captured. A particle size analyzer (Malvern Master Sizer 2000 E, UK) was used to measure the average particle size and the particle size distribution. Also, the physical stability of the niosomal formulations was determined by size variations in 3 days, and 1, 3 and 6 months after production (Verma and Stellacci [@CR23]).

Benzoxonium chloride released from the niosomal formulations was studied with an all-glass Franz diffusion cell. An acetate cellulose dialysis membrane (12--14 KD MW cut off, Visking tube, USA) was soaked in deionized (DI) water overnight before the experiment. The receptor compartment was filled with DI water and 1 mL of each formulation was placed on the cellulose acetate membrane. Aliquots of 1 mL were withdrawn at predetermined time intervals of 0, 15, 30, 60, 90, 120, 150, 180 and 240 min and replaced with fresh medium maintained at 37 ± 0.5 °C. The released drug was quantified spectrophotometrically at 208 nm. The mean cumulative drug release level was plotted against time to study the mechanism of drug release in order to compare the release profiles of the different formulae.

For encapsulation efficiency level (EE%), non-entrapped drug was separated from the niosome encapsulated one by centrifugation at 14,000 rpm for 30 min. Three volumes, each of 1 mL isopropyl alcohol, were used to wash the isolated pellets, followed by re-centrifugation under the same conditions to completely remove the non-entrapped drug until a clear solution was obtained. After proper dilution, the benzoxonium chloride concentration was determined spectrophotometrically at 208 nm and analyzed by the following equation: % EE = (Total drug − free drug/Total drug) × 100.

In vitro assays {#Sec6}
---------------

The cytotoxicity effects of benzoxonium chloride and niosomal forms to evaluate the safety of this compound were checked by MTT assay on J774 A.1 ATCC^®^TIB-67™ purchased from the Pasteur Institute of Iran with doses between 1.0 and 300.0 μg/mL. In brief, the cultured macrophages (5 × 10^4^) at 37 °C and 5% CO~2~ were treated with various concentrations of drugs in 96-well tissue culture plates and kept for standard time at 48 h. Routinely, 10 µL of MTT stock solution (5 mg/mL) was added to each well of the tissue culture plates. After incubation for 3 to 4 h, the medium was removed and acidic isopropanol (0.04--0.1 NHCL in absolute isopropanol) was added to stop the reactions. Absorbance was measured by an ELISA reader (BioTek-ELX800 Winooski, Vermont, USA) at a wavelength of 490 nm.

For the promastigote assay, promastigotes of *L*. *tropica* (MHOM/IR/2002/Mash2), which was prepared by Leishmaniasis Research Center (Kerman, Iran), in logarithmic growth phase (10^5^cells/mL) were treated with different concentrations of benzoxonium chloride, its niosomal forms or MA alone (positive control) and were evaluated by an MTT assay. Promastigotes without drug and complete medium with no promastigotes and drugs were used as untreated control and blank, respectively. All the treatments were repeated thrice and absorbance was measured at 490 nm.

For the intra-macrophage amastigote assay, 100 μL of macrophage J774A (1 × 10^5^/mL) was added to each slide (75 × 25 mm) in the sterile Petri dish and incubated for 6 h at 37 °C and 5% CO~2~. The macrophages were then infected at a 1:10 ratio (macrophage: promastigote in stationary phase of *L. tropica*) and incubated for 24 h at 37 °C, 5% CO~2~, and 85% relative humidity. After 24 h, drugs concentrations similar to the promastigote assay were added thrice. After confirmation of macrophage infection levels of above 80% (with light microscopy), 100 μL of drugs dilution was added to each slide. The drug and host cell containing amastigotes without drug and complete medium without parasite were considered as untreated control and blank, respectively. After standard time of 48 h at 37 °C for incubation, the slides were stained with Wright Giemsa and the number of amastigotes in 100 macrophages was evaluated by direct observation with an optical microscope. The medium was removed and the slides were fixed with 100% methanol for 2 min and stained by Wright Giemsa for 15 min. The number of amastigotes in 100 macrophages was evaluated for each treatment by direct examination with a light microscope. The dose-response curves and the IC~50~ values were calculated by using the probit test in SPSS software.

Determination of apoptosis and necrosis {#Sec7}
---------------------------------------

Apoptosis and necrotic cell death were evaluated with PE Annexin V and 7-Amino Actinomycin (7-AAD). Promastigotes of *L. tropica* (1 × 10^6^) were seeded into the micro tube and treated with the desired concentrations of drugs and incubated at 25 °C for 48 h. After incubation, the promastigotes were washed twice with cold PBS and were suspended in 1 × binding buffer. Then, in a 5-mL culture tube, 5 µL of PE Annexin V and 5 µL of 7-AAD were added and incubated for 15 min in the dark at room temperature. Finally, they were analyzed by flow cytometry (BD FACSCalibur™) within 1 h.

mRNA transcripts and RT-PCR {#Sec8}
---------------------------

The levels of expression of IL-10 and IL-12 in macrophage J774A1 and metacaspase genes in the promastigotes of *L. tropica* were evaluated by a quantitative real-time PCR (q-PCR) assay. RNA was extracted by using the RNeasy mini kit (Qiagen, Chatsworth, CA) from various concentrations of the best selective drug and the untreated control group. The cDNA was made by a first-strand cDNA synthesis kit (Takara Bio, Inc., Shiga, Japan).

The quantitative real time reaction was carried out by the Rotorgene cycler system (Rotorgene 3000 cycler system, Corbett Research, Sydney, Australia) and a SYBR Green experiment (SYBR Premix Ex Taq™ II, Takara, Clontech). GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) for the gene expression of IL-12 and IL-10 in macrophage J774 A and RPS18 Ribosomal protein (S18) for the gene expression of metacaspase in promastigote of *L. tropica* were used as the reference genes (Table [1](#Tab1){ref-type="table"}) (Chandra and Naik [@CR7]; Satheesh Kumar et al. [@CR21]).Table 1Sequences of forward and reverse primers and reference genes used for quantitative real time PCRTemplateForward sequence (5′--3′)Reverse sequence (5′--3′)Product size (bp)IL-12CTGGAGCACTCCCCATTCCTAGCAGACATTCCCGCCTTTG160IL10CTTACTGACTGGCATGAGGATCAGCAGCTCTAGGAGCATGTGC101Meta caspaseCAGCAACAATTCCTGGCGATAAAGTTTGAAGTAAAAGGAGACAATTTGG140S18GTTGAGGTGCGTGGTCTGTCTGCAGGTTGCTCAGGAGCTT166GAPDHAGCTTCGGCACATATTTCATCTGCGTTCACTCCCATGACAAACA89

The cDNA was amplified by 40 three-step cycles (10 s at 95 °C for denaturation of DNA, 15 s at 58 °C for primer annealing, and 20 s at 72 °C for extension).The final temperature was 65 °C for 1 min. The ΔCT was obtained by the following formula: \[ΔCT = CT (target) \_ CT (reference)\]. Gene expression level was specified by the 2^−ΔCt^ method. Also, the fold increase (FI) was calculated by the comparative threshold method (2^−ΔΔCT^).

Data analysis {#Sec9}
-------------

The data analysis was performed by using SPSS software version 20 (Chicago, IL, USA). The differences between the groups were assessed by using ANOVA and *t* test. The 50% inhibitory concentrations (IC~50~) and dose-response curves were analyzed with probit in SPSS software. *P* values \< 0.05 were regarded as significant. The selectivity indexes were expressed as the ratio between CC~50~ macrophage/IC~50~ amastigote forms. The graphs were designed with GRAPHPAD PRISM 6 (Graph Pad Software Inc., San Diego, CA, USA).

Results {#Sec10}
=======

Preparation and characterization of niosomes {#Sec11}
--------------------------------------------

The prepared niosomes were mostly multilamellar (MLV) round vesicles because we used the lipid film hydration method. Span/Tween 40 (ST40, 7:3 molar ratio, NB~1~) and Span/Tween 60 (ST60, 6:4 molar ratio, NB~2~) were chosen as the superior formulations (Fig. [2](#Fig2){ref-type="fig"}). Considering that the hydration method of the fatty layer was used in manufacture of niosomes, the diameters of the niosomes were larger than 5 µm. Size analysis of the two formulations showed log-normal particle size distribution curves after 3 days, but NB1 did not have good physical stability as depicted by their widely-changed size distribution curves after 1, 3 and 6 months of storage at refrigerator temperature (Fig. [3](#Fig3){ref-type="fig"}). The encapsulation efficiency (more than 96%) was calculated for benzoxonium chloride in the ST40 and ST60 niosomes. The release profile of the niosomal forms of the entrapped material is shown in Fig. [4](#Fig4){ref-type="fig"}. The release rate of NB~2~ was less than NB~1~ with a milder gradient so that 10% of the drug was not released after 4 h.Fig. 2Light microscopy of niosomal forms of benzoxonium chloride ( × 100 magnification) **a** Span/Tween 40 (7:3 m.r.), **b** Span/Tween 60 (6:4 m.r.) prepared by film hydration methodFig. 3The particle size distribution graph by frequency of **a** Span Tween 40 (7:3 m.r.) and **b** Span Tween 60 (6:4 m.r.) after 3 days, 1, 3 and 6 months storage at refrigeratorFig. 4The released amount of niosomal forms of benzoxonium chloride (%) at different time intervals (mean ± SD, n = 3)

In vitro assay {#Sec12}
--------------

According to the survey of cytotoxic assay, there wasn't any cytotoxicity in the different concentrations used in our study. The 50% inhibitory concentrations (IC~50~) of promastigote and amastigote treated with the drugs are listed in Table [2](#Tab2){ref-type="table"}. The NB~2~ formulation showed the most activity as evidenced by the IC~50~ values of 90.7 ± 2.7 μg/mL and 25.4 ± 0.6 μg/mL for the promastigote and amastigote forms, respectively, after 48 h of incubation. MA showed IC~50~ of 536.6 ± 40 and 101.8 ± 4.2 μg/mL against the promastigote and amastigote forms, respectively. We observed a dose dependent antileishmanial activity for both forms, as presented in Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}. The IC~50~ values of all the drugs demonstrated a significant difference with the positive control (*p* \< 0.001) on the promastigote and amastigote forms, while no significant difference was found between the IC~50~ rates of NB~1~and NB~2~ in the promastigote assay.Table 2Antileishmanial activities calculated for benzoxonium chloride (B), niosomal forms (NB~1~ and NB~2~) and meglumine antimoniate (MA)CompoundBNB~1~NB~2~MAPromastigote IC~50~^a^ (µg/mL)210.2 ± 6.1113.1 ± 6.290.7 ± 2.7536.6 ± 40Amastigote IC~50~^a^ (µg/mL)147.0 ± 5.456.3 ± 1.625.4 ± 0.6101.8 ± 4.2Data represent the mean value ± standard deviation^a^50% inhibitory concentrationFig. 5The inhibition of promastigotes in the presence of various concentrations of benzoxonium chloride (B), niosomal forms (NB~1~ and NB~2~) and meglumine antimoniate (MA) after 48 h incubationFig. 6The inhibition of amastigotes in the presence of various concentrations of benzoxonium chloride (B), niosomal forms (NB~1~ and NB~2~) and meglumine antimoniate (MA) after 48 h incubation

The mean number of amastigotes in 100 macrophages in triplicates is shown in Table [3](#Tab3){ref-type="table"}. Various concentrations of the drugs were able to significantly inhibit the multiplication rate of the amastigotes in each macrophage as compared with the untreated control (*P* \< 0.01).Table 3Comparative evaluation of the effect of benzoxonium chloride (B), niosomal forms (NB~1~ and NB~2~) and meglumine antimoniate (MA) with untreated control on intramacrophage amastigote of *Leishmania tropica*DrugsBNB~1~NB~2~MAConcentration (µg/µL)No of amastigote  ± SD*P* valueNo of amastigote  ± SD*P* valueNo of amastigote  ± SD*P* valueNo of amastigote  ± SD*P* value0.00 (control)60.71 ± 1.46NR60.71 ± 1.46NR60.71 ± 1.46NR60.71 ± 1.46NR12.5048.31 ± 0.610.0137.03 ± 0.950.0135.76 ± 0.320.0154.20 ± 1.060.0225.0040.2 ± 0.720.0133.93 ± 0.700.0130.40 ± 0.960.0141.86 ± 1.020.0150.0034.56 ± 0.580.0132.93 ± 0.800.0125.56 ± 0.510.0134.46 ± 2.050.01100.0032.96 ± 0.550.0129.03 ± 0.550.0120.73 ± 0.640.0131.46 ± 1.910.01150.0031.42 ± 0.670.0124.00 ± 0.900.0118.13 ± 0.410.0128.16 ± 2.010.01200.0030.16 ± 0.860.0122.54 ± 0.360.0117.23 ± 0.490.0122.96 ± 2.620.01300.00----21.20 ± 0.620.0116.83 ± 0.560.0120.36 ± 2.510.01*NR* not related

Selectivity Index \[SI (Selectivity Index) = CC~50~ macrophage/IC~50~ ≥ 10 non-toxic for amastigote forms\] was also calculated for the medications, and the highest level was obtained at NB~2~ (12.5).

Apoptotic cell determination {#Sec13}
----------------------------

The levels of apoptotic, necrotic, and viable cells in the closest concentration of each drug to its IC~50~ dose were determined and compared with the untreated control and similar concentrations with the positive control (MA). The rate of apoptosis in B (200 µg/mL) was very low, while this rate increased significantly in the niosomal formulations. The rate of apoptosis in NB~1~ (100 µg/mL) and in NB~2~ (100 µg/mL) was 27.21% and 26.65%, respectively. These values were approximately equal to the positive control (27.4%) at the same concentration. The rate of apoptosis was 0.34% in the untreated control (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Flow cytometry analysis demonstrating early and late apoptosis as well as necrotic cells after treatment with the closest concentration of IC~50~ doses of benzoxonium chloride (B), niosomal forms (NB~1~ and NB~2~) and similar concentrations in meglumine antimoniate (MA), after 48 h

RT-PCR analysis {#Sec14}
---------------

Gene expression in response to *L. tropica* was evaluated against NB~2~. The amplification efficiency of each gene was verified by three dilutions (12.5, 50, and 150 µg/mL) (Fig. [8](#Fig8){ref-type="fig"}). A comparison of the mean $\documentclass[12pt]{minimal}
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                \begin{document}$$ 2^{{ - \Delta \Delta {\text{C}}}}_{\text{T}} $$\end{document}$ between untreated and treated with NB and MA showed significant changes in mRNA expression of IL-12, IL-10, and the metacaspase genes, except for the concentration of 12.5 µg/mL between untreated and MA (Fig. [8](#Fig8){ref-type="fig"}). The mean (±SE) FI when treated with NB (150 µg/mL) for IL-12, IL-10, and metacaspase genes was 11.28 ± 0.18, 0.23 ± 0.05, and 7.02 ± 0.07, respectively. For all the genes at various concentrations, there was a significant difference (*P* \< 0.05) between NB and the positive control (MA).Fig. 8Effect of different concentrations of NB~2~ and positive control (MA) on genes expression of IL-12, IL-10, and metacaspase of *L. tropica* (comparison between NB and MA with untreated control; *P* \< 0.05\*, *P* \< 0.01\*\*, *P* \< 0.001\*\*\*)

Discussion {#Sec15}
==========

Leishmaniasis is a serious global challenge and all chemical treatments have severe side effects, or there is emerging resistance to these drugs (Ghorbani and Farhoudi [@CR11]). The studies evaluating the drug delivery methods were found to be very promising. Niosomes have potential as new and selective drugs for treating important diseases, including leishmaniasis (Kazi et al. [@CR14]). Previous studies have evaluated the anti-leishmanial effects of Thio-Ben on patients (Daie Parizi et al. [@CR9]) and in the present work, we evaluated the *in vitro* leishmanicidal effects of benzoxonium chloride (one of the components of Thio-Ben) and its niosomal forms against different forms of the parasite (*L. tropica*).

Benzoxonium chloride was previously shown to be promising antibacterial, certain antiprotozoal, and anti-septic agents (Kim et al. [@CR15]). Our *in vitro* studies showed a leishmanicidal activity for the drug and its niosomal forms. Among the tested drugs, the NB~2~ formulation showed the most potent anti-leishmanial effect against different stages of the parasite by *in vitro* tests.

Anti-promastigote activity is considered a useful tool for drug evaluation, even though this form of the parasite is only found in the sand fly. The anti-promastigote activities of these drugs were observed. Also, amastigote in clinical stage is responsible for retaining the infection in the mammalian host, the anti-amastigote activity of B and its niosomal forms were evaluated in murine macrophages infected *in vitro*. A strong anti-amastigote activity was observed in all the tested drugs, as indicated by the significant decrease of intracellular infection. As shown in Table [2](#Tab2){ref-type="table"} and Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}, generally all the drugs inhibited the growth of *L. tropica* promastigotes and amastigotes; although, the NB~2~ formulation presented the highest antileishmanial activity. The drug selectivity index (SI) of NB~2~ was higher than the other drugs. Actually, NB~2~ is 12.5 times safer for the macrophages than for the amastigotes of *L. tropica* (Almeida-Souza et al. [@CR2]).

A comparison of the various selected niosomal forms revealed that NB~2~ (Span/Tween 60, 6:4 molar ratio), its size and stability were better than the other formulation (Span/Tween 40, 7:3 molar ratio). The stability of the prepared NB~2~ was high with no significant changes in the sizes when it was stored at 4 °C for 6 months. Since cholesterol is essential for the formation of niosomes and effects stability, size and shape, therefore, a high content of cholesterol composition in NB~2~ possibly caused the stability of this formulation (Essa [@CR10]; Kazi et al. [@CR14]). Similarly, in a previous study, the use of Span 60 exhibited lower change in particle size for preparing niosomes containing autoclaved *L. major* (Pardakhty et al. [@CR20]).

Our results revealed that the effects of the niosomal form of benzoxonium chloride against the promastigote form were partially associated with apoptosis and their rate of apoptosis was equal to the positive control. There is some evidence that apoptosis-like programmed cell death (PCD) has also occurred in some unicellular organisms, such as *Leishmania* (Besteiro et al. [@CR6]), which could potentially involve metacaspase (Williams et al. [@CR25]). Metacaspase plays a crucial role in the induction of PCD and it is an apoptotic execution switch, and *L. major* metacaspase can complement an apoptosis cell death phenotype in yeast (González et al. [@CR12]). In our study, the level of metacaspase gene expression increased with increasing drug concentrations (NB), which was significantly higher than the positive control (MA). This increase in the expression level of metacaspase triggers the host's immune response to Th1 modality. Also, IL-12 is necessary for Th1 polarization and it is crucial for defense against parasitic pathogens that affect the immune response to invading *Leishmania* parasite. Changes in IL-12 gene expression relative to IL-10 expression t switch cell-mediated immunity toward a Th1 immune response (Martorelli et al. [@CR17]).

In the present study, we demonstrated the ability of niosome of benzoxonium chloride to initiate a Th1 cell-mediated immune response. Actually, with increasing the concentration of this drug, the expression of IL-10 declined and the expression level of IL-12 increased as expected, thereby showing an immunomodulatory role of the drug as the primary mode of action for treating ACL.

The niosomal formulations provided improved and great anti-leishmanial activities of benzoxonium chloride and promoted a protective immune response that provided effective *L. tropica* elimination with no excessive tissue destruction.
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